Predictive molecular markers in the adjuvant therapy of breast cancer: State of the art in the year 2002

International Journal of Clinical Oncology

Volumn 7, Issue 4, 2002, Pages 245-253

  Di Leo, Angelo ^a   Cardoso, Fatima ^a   Durbecq, Virginie ^a   Giuliani, Rosa ^a   Mano, Max ^a   Atalay, Gul ^a   Larsimont, Denis ^a   Sotiriou, Christos ^a   Biganzoli, Laura ^a   Piccart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant therapy; Breast cancer; Molecular markers; Predictive markers

Indexed keywords

ALPHA TUBULIN; ANTHRACYCLINE DERIVATIVE; AROMATASE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ETOPOSIDE; FLUOROURACIL; KI 67 ANTIGEN; MELPHALAN; METHOTREXATE; MOLECULAR MARKER; PACLITAXEL; PREDNISONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TAU PROTEIN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DISEASE MARKER; DRUG EFFICACY; DRUG UTILIZATION; EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL INFORMATION; METASTASIS; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 18544370405     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200036     Document Type: Conference Paper

References (59)

1. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
2. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
3. A multicentre randomized trial of tamoxifen vs tamoxifen plus epirubicin in postmenopausal women with node-positive breast cancer
4. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: 8-Year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil
5. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: 10-Year analysis. An Intergroup study
6. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors
7. Polychemotherapy for early breast cancer: An overview of the randomized trials
8. Meeting highlights: International Consensus Panel on the Treatment of Primary Cancer
9. Tamoxifen for early breast cancer: An overview of the randomized trials
10. Amplification of the c-erb B2 oncogene in prognosis of breast adenocarcinoma
11. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
12. Twenty-year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb B2 expression and tamoxifen efficacy
13. ErbB2 status and the benefit from 2 or 5 years of adjuvant tamoxifen in postmenopausal early stage breast cancer
14. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment
15. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
16. Value of epidermal growth factor receptor, Her2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients
17. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study
18. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer
19. Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer
20. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy in premenopausal women with node-positive breast cancer
21. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination by epirubicin
22. HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma
23. Prognostic importance of c-erb B2 expression in breast cancer
24. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
25. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biological variables
26. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
27. HER-2 and topoisomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
28. Her2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer
29. erb B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
30. erb-B2, p-53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
31. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
32. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
33. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases
34. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridisation and immunohistochemistry
35. Evaluation of HER-2/neu by different immunohistochemistry methods and fluorescence in situ hybridization in more than 300 archival primary breast cancer samples: Implications for daily laboratory practice
36. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
37. Loss of tumor marker-imunostaining intensity on stored paraffin slides of breast cancer
38. Evaluation of HER-2, p53, bcl-2, topoisomerase II-α, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes
39. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer
40. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer
41. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
42. Evaluation of HER2/neu protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER2/neu testing
43. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
44. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
45. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erb B2 overexpression in breast cancer
46. Characterization of topoisomerase IIα gene amplification and deletion in breast cancer
47. Amplification of topoisomerase IIα is a strong predictor of response to epirubicin-based chemotherapy in HER-2/neu positive breast cancer
48. Anti-topoisomerase drug action and resistance
49. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
50. The biochemistry of P-glycoprotein-mediated multidrug resistance
51. Biology of the multidrug resistance-associated protein, MRP
52. HER-2/neu amplification and response to doxorubicin/paclitaxel in women with metastatic breast cancer
53. Correlation of circulating c-erb B2 extracellular domain (HER-2) with clinical outcome in patients with metastatic breast cancer
54. HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
55. p-53 genotype and major response to anthracycline or paclitaxel based neoadjuvant treatment in breast cancer patients
56. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumor-bearing mice
57. Evaluation of microtubule associated parameters (MTAPs) as predictive markers for advanced breast cancer (ABC) patients treated with docetaxel
58. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
59. Activation (tyrosine phosphorylation) of erbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer